{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:43:20Z","timestamp":1722890600768},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s40261-018-0737-y","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T22:58:25Z","timestamp":1547074705000},"page":"109-111","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Response to Comments on \u201cPharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study\u201d"],"prefix":"10.1007","volume":"39","author":[{"name":"Evocalcet Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadao","family":"Akizawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryutaro","family":"Shimazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanari","family":"Shiramoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,10]]},"reference":[{"key":"737_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0738-x","author":"NR Srinivas","year":"2018","unstructured":"Srinivas NR. Comments on \u201cPharmacokinetics, pharmacodynamics, and safety of the novel calcimimetic agent evocalcet in healthy Japanese subjects: First-in-Human Phase I study\u201d. Clin Drug Investig. 2018. \n                    https:\/\/doi.org\/10.1007\/s40261-018-0738-x\n                    \n                  .","journal-title":"Clin Drug Investig."},{"issue":"10","key":"737_CR2","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s40261-018-0687-4","volume":"38","author":"T Akizawa","year":"2018","unstructured":"Akizawa T, Shimazaki R, Shiramoto M, Fukagawa M, Evocalcet Study Group. Pharmacokinetics, pharmacodynamics, and safety of the novel calcimimetic agent evocalcet in healthy Japanese subjects: first-in-human phase I study. Clin Drug Investig. 2018;38(10):945\u201354.","journal-title":"Clin Drug Investig."},{"key":"737_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-018-1635-6","author":"T Shigematsu","year":"2018","unstructured":"Shigematsu T, Shimazaki R, Fukagawa M, Akizawa T, Evocalcet Study Group. Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients. Clin Exp Nephrol. 2018. \n                    https:\/\/doi.org\/10.1007\/s10157-018-1635-6\n                    \n                  \n                           (Epub 29 Aug 2018).","journal-title":"Clin Exp Nephrol"},{"issue":"48","key":"737_CR4","first-page":"1966","volume":"70","author":"CS So","year":"1975","unstructured":"So CS, Batrice L, Volger E. Electrocardiographic changes in electrolyte inbalance. Part 2: alterations in serum calcium [author\u2019s transl; in German]. Med Klin. 1975;70(48):1966\u20138.","journal-title":"Med Klin"},{"issue":"4","key":"737_CR5","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1053\/ajkd.2002.32005","volume":"39","author":"ER Beaubien","year":"2002","unstructured":"Beaubien ER, Pylypchuk GB, Akhtar J, Biem HJ. Value of corrected QT interval dispersion in identifying patients initiating dialysis at increased risk of total and cardiovascular mortality. Am J Kidney Dis. 2002;39(4):834\u201342.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"737_CR6","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1210\/jc.2010-2969","volume":"96","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Post WS, Dalal D, et al. Serum 25-hydroxyvitamin D, calcium, phosphorus, and electrocardiographic QT interval duration: findings from NHANES III and ARIC. J Clin Endocrinol Metab. 2011;96(6):1873\u201382.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"737_CR7","first-page":"272","volume":"33","author":"FJ Borrego-Utiel","year":"2013","unstructured":"Borrego-Utiel FJ, P\u00e9rez-del Barrio MDP, Biechy-Baldan MDM, Segura-Torres P. Cinacalcet may prolong the QT interval in patients on haemodialysis with secondary hyperparathyroidism. Nefrologia. 2013;33(2):272\u20133.","journal-title":"Nefrologia."},{"issue":"7","key":"737_CR8","first-page":"520","volume":"16","author":"G Temiz","year":"2016","unstructured":"Temiz G, Yal\u00e7\u0131n AU, Mutluay R, Bozac\u0131 \u0130, Bal C. Effects of cinacalcet treatment on QT interval in hemodialysis patients. Anatol J Cardiol. 2016;16(7):520\u20133.","journal-title":"Anatol J Cardiol."},{"issue":"15","key":"737_CR9","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516\u201325.","journal-title":"N Engl J Med"},{"issue":"1","key":"737_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1053\/j.ajkd.2005.04.013","volume":"46","author":"C Charytan","year":"2005","unstructured":"Charytan C, Coburn JW, Chonchol M, et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis. 2005;46(1):58\u201367.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"737_CR11","first-page":"12","volume":"3","author":"SS Beladi-Mousavi","year":"2015","unstructured":"Beladi-Mousavi SS, Faramarzi M. Calcimimetic agents in the management of secondary hyperparathyroidism among patients with end-stage renal disease; a review article. J Parathyr Dis. 2015;3(1):12\u20139.","journal-title":"J Parathyr Dis."},{"issue":"1","key":"737_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2215\/CJN.12941213","volume":"10","author":"F Tentori","year":"2015","unstructured":"Tentori F, Wang M, Bieber BA, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2015;10(1):98\u2013109.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"737_CR13","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.2215\/CJN.11501210","volume":"6","author":"T Akizawa","year":"2011","unstructured":"Akizawa T, Kido R, Fukagawa M, et al. Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns. Clin J Am Soc Nephrol. 2011;6(9):2280\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"737_CR14","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.kint.2018.05.013","volume":"94","author":"M Fukagawa","year":"2018","unstructured":"Fukagawa M, Shimazaki R, Akizawa T, Evocalcet Study Group. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2018;94(4):818\u201325.","journal-title":"Kidney Int"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-018-0737-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0737-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0737-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T19:13:17Z","timestamp":1578597197000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-018-0737-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["737"],"URL":"https:\/\/doi.org\/10.1007\/s40261-018-0737-y","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"10 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received to assist in the preparation of this response.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"TA has received consulting fees from Kyowa Hakko Kirin Co, Ltd, Astellas Pharma Inc., Bayer Yakuhin, Ltd, Fuso Pharmaceutical Industries, Ltd, Japan Tobacco Inc., Ono Pharmaceutical Co, Ltd and NIPRO Industry; as well as lecture fees from Kyowa Hakko Kirin Co., Ltd, Chugai Pharmaceutical Co., Ltd, Bayer Yakuhin, Ltd, Kissei Pharmaceutical Co, Ltd, Torii Pharmaceutical Co, Ltd, and Ono Pharmaceutical Co., Ltd. RS is employed by Kyowa Hakko Kirin Co., Ltd, which funded the original research. MF has received consulting fees from Kyowa Hakko Kirin Co., Ltd and Ono Pharmaceutical Co. Ltd; as well as lecture fees from Kyowa Hakko Kirin Co., Ltd, Bayer Yakuhin, Ltd, Torii Pharmaceutical Co., Ltd and Ono Pharmaceutical Co., Ltd, and grants from Kyowa Hakko Kirin Co., Ltd and Bayer Yakuhin Ltd. MS has no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}